Dr Paolo Nuciforo | Head Molecular Oncology Group
Vall d'Hebron Institute of Oncology | Spain

Dr Paolo Nuciforo, Head Molecular Oncology Group, Vall d'Hebron Institute of Oncology

Paolo Nuciforo, MD, PhD, board certified Pathologist, is the Principal Investigator of the Molecular Oncology group at Vall d`Hebron Institute of Oncology (VHIO). He has 15+ years of experience in oncology translational medicine and drug development both in academic and pharmaceutical environment. He co-authored over 80 publications in peer-reviewed journals with a main focus on discovery and validation of novel biomarkers for precision oncology using tissue-based technologies. During the last two years, he has been working in deciphering the impact of Fusobacterium nucleatum infection in colorectal cancer evolution and in developing in situ visualization approaches to establish the invasive capabilities of microbes which could be crucial in more precisely identifying those patients who would be most likely to benefit from treatments targeting the cancer-associated microbiota.

Appearances:



Oct 28th Pre-Congress Workshops @ 14:00

Workshop D: Improvement of cancer patient treatment outcomes: Using liquid biopsies & novel biomarkers for predicting prognosis and response

Join this workshop to learn about new and emerging biomarkers, and discuss how to overcome the limitations of liquid biopsiesBiomarker Strategy
  • Using a proteomic approach to identify new biomarkers for risk detection and response to therapy
  • Developing and implementing biomarker strategies into early clinical trial designs
  • Emerging Biomarkers: Microbiome
  • Liquid biopsy for what purpose? Relapse? Prediction purposes?
  • -Insight into use of liquid biopsy in solid tumours
  • Application of liquid biopsies in haematological malignancies
  • Circulating cancer biomarkers, what can we do?
last published: 19/Sep/19 13:06 GMT

back to speakers

Sign Up for Event Updates